NCT02302339 - A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma | Biotech Hunter

Enrollment

132

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

June 14, 2018

Study Completion Date

October 3, 2018

Conditions

Melanoma

Interventions

DRUG

glembatumumab vedotin

DRUG

glembatumumab vedotin and varlilumab

DRUG

glembatumumab vedotin and PD-1 targeted checkpoint inhibitor (nivolumab OR pembrolizumab)

DRUG

glembatumumab vedotin and CDX-301

Trial Locations (14)

10016

New York University School of Medicine, New York

27710

Duke University Medical Center, Durham

30341

Northside Hospital Cancer Institute, Atlanta

33140

Mount Sinai Comprehensive Cancer Center, Miami Beach

33407

Florida Cancer Specialists, West Palm Beach

33916

Florida Cancer Specialists, Fort Myers

37203

Tennessee Oncology, Nashville

37232

Vanderbilt-Ingram Cancer Center, Nashville

48202

Henry Ford Hospital, Detroit

60637

University of Chicago Medicine, Chicago

75246

Baylor Research Institute-Sammons Cancer Center, Dallas

90025

The Angeles Clinic and Research Institute, Los Angeles

94117

Northern California Melanoma Center/St. Mary's Medical Center, San Francisco

02115

Dana Farber Cancer Institute, Boston